Baiya SARS CoV 2 Vax 2
Alternative Names: Baiya-SARS-CoV-2-Vax-2; SARS-CoV-2 receptor-binding domain based vaccineLatest Information Update: 28 Jan 2022
At a glance
- Originator Baiya Phytopharm
- Class COVID-19 vaccines; Protein vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 19 Jan 2022 Preclinical trials in COVID-2019 infections (Prevention) in Thailand (IM) before January 2022
- 19 Jan 2022 Baiya Phytopharm plans a phase I trial for COVID-2019 infections (Prevention) in Thailand (IM) (NCT05197712)